This document was prepared as a pre-read for the meeting of the PAHO Malaria Technical Advisory Group and is not an official document of PAHO/WHO



Pan American Health Organization



World Health Organization

REGIONAL OFFICE FOR THE Americas

MALARIA TECHNICAL ADVISORY GROUP MEETING

7-8 June, 2017. Washington DC, USA

REGIONAL GUIDANCE ON THE IMPLEMENTATION OF G6PD TESTING AND RADICAL CURE IN *P. VIVAX* ENDEMIC COUNTRIES

MARIA PAZ ADE REGIONAL MALARIA PROGRAM PAHO/WHO/WDC





FIRST PART BACKGROUND







Testing for G6PD deficiency





FIGURE 2 Endemicity of *P. vivax* in 2010

Testing for G6PD deficiency for safe use of primaquine in radical cure of *P. vivax* and *P. ovale* malarit FIGURE 1



350 million people affected globally

Prevalence varies from 3% to 35% in tropical areas

>180 different G6PD deficiency genetic variants

Two of the most prevalent variants represent the two ends of the severity spectrum:

- Africa A– : sub-Saharan Africa, and African-Americans (mild)
- Mediterranean: Europe, West and Central Asia, and northern India (severe)






WHO RECOMMENDATIONS:

- The G6PD status of patients should be used to guide administration of primaquine for preventing relapse.
- To prevent relapse, treat P. vivax or P. ovale malaria children and adults (except pregnant women, infants aged <6 months, women breastfeeding infants aged <6 months, women breastfeeding older infants unless they are known not to be G6PD deficient and people with G6PD deficiency) with a 14-day course of primaquine at 0.25–0.5 mg/kg body weight daily in all transmission settings.
- In people with G6PD deficiency, consider preventing relapse by giving primaquine base at 0.75 mg/kg body weight once a week for 8 weeks, with close medical supervision for potential primaquine-induced haemolysis.
- When a patient's G6PD status is unknown and G6PD testing is not available, a decision to prescribe primaquine must be based on an assessment of the risks and benefits of adding primaquine.
- For women who are pregnant or breastfeeding, consider weekly chemoprophylaxis with chloroquine until delivery and breastfeeding are completed; then, on the basis of the woman's G6PD status, treat with primaquine to prevent future relapse





HOW





* More information on risk-benefit assessment, patient counselling and medical supervision is provided in the text.





Contextual elements in the Americas









Contextual elements in the Americas

Risk

- Factors in favour of use of PQ without testing:
 - Low prevalence of G6PD deficiency in general, mainly the A- variants
 - Widespread use of primaquine for many decades, without reported side effects
- Factors against the use of PQ without testing:
 - Reported cases of severe haemolysis in some localities in Brazil, including reports from autopsy studies;
 - Population at greater malaria risk living in rural communities, hard to reach population (Amazon);

Additional issues to consider for a risk-benefit analysis:

 Population heterogeneity and Amerindian genealogy in large proportions of the populations. High variability in G6PDd findings even within the same local areas in specific countries (Pacific coast in Colombia from 2% - 12%).





Contextual elements in the Americas

Benefits

- Predominance of P. vivax infection in areas close to elimination as well as in areas of high burden.
- High relapse rates. Prevention of relapses is a key element to reduce vivax transmission and achieve malaria elimination in the Americas.





SECOND PART **OBJECTIVES**







Regional Guidance on WHO policy brief

- Ensure continuity in the use of primaquine for P. vivax radical cure in countries of the Americas and the transition based on the risk-benefit assessment owing to the current unavailability of a point of care diagnostic test for G6PD status;
- Support countries in introduction and scale up of G6PD deficiency diagnosis and good case management practices to prevent severe consequences in malaria patients due to haemolysis.











Main areas to be strength

Wherever primaquine is administered with or without G6PD testing the national health authorities should implement the following practices:


- Patients counselling
- Health service capacity
- Pharmacovigilance





A. Treatment choices when the G6PD deficiency status of the patient is unknown (G6PDd test not available)

1. Countries or areas with low G6PD deficiency prevalence




* if observed treatment with basic response is available





A. Treatment choices when the G6PD deficiency status of the patient is unknown (G6PDd test not available)

2. Countries or areas with high G6PD deficiency prevalence




* With regular supervision by health professionals.






B1.Treatment choices when the G6PD deficiency status of the patient is known (G6PDd test available).



REGIONAL OFFICE FOR THE Americas

B2. Treatment choices when the G6PD deficiency status of the patient is known (G6PDd test available)










Questions

- Comments on the strategy and flowchart
- Do we need to support G6PD deficiency prevalence and variants studies in the Region?
- Operational issues behind implementation of G6PDd testing (procurement, quality control, training...)





FIGURE 1 Prevalence of G6PD deficiency





Pan American Health Organization



World Health Organization

REGIONAL OFFICE FOR THE Americas